Lukas Biomedical Past Earnings Performance
Past criteria checks 0/6
Lukas Biomedical's earnings have been declining at an average annual rate of -31.6%, while the Biotechs industry saw earnings growing at 19.2% annually. Revenues have been growing at an average rate of 8.1% per year.
Key information
-31.6%
Earnings growth rate
-24.7%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | 8.1% |
| Return on equity | -16.9% |
| Net Margin | -20.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Lukas Biomedical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 232 | -47 | 100 | 77 |
| 30 Sep 23 | 222 | -43 | 96 | 70 |
| 30 Jun 23 | 212 | -38 | 87 | 61 |
| 31 Mar 23 | 198 | -44 | 87 | 57 |
| 31 Dec 22 | 185 | -50 | 90 | 56 |
| 30 Sep 22 | 176 | -51 | 88 | 56 |
| 30 Jun 22 | 167 | -52 | 86 | 57 |
| 31 Mar 22 | 162 | -51 | 85 | 56 |
| 31 Dec 21 | 158 | -49 | 84 | 55 |
| 30 Sep 21 | 164 | -41 | 86 | 48 |
| 30 Jun 21 | 169 | -32 | 88 | 42 |
| 31 Mar 21 | 175 | -21 | 88 | 38 |
| 31 Dec 20 | 181 | -11 | 88 | 35 |
| 30 Sep 20 | 176 | -9 | 94 | 42 |
| 30 Jun 20 | 171 | -7 | 100 | 48 |
| 31 Mar 20 | 162 | -7 | 87 | 38 |
| 31 Dec 19 | 153 | -7 | 74 | 29 |
| 31 Dec 18 | 132 | -20 | 58 | 23 |
| 31 Dec 17 | 128 | -11 | 50 | 18 |
Quality Earnings: 6814 is currently unprofitable.
Growing Profit Margin: 6814 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6814 is unprofitable, and losses have increased over the past 5 years at a rate of 31.6% per year.
Accelerating Growth: Unable to compare 6814's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6814 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.8%).
Return on Equity
High ROE: 6814 has a negative Return on Equity (-16.9%), as it is currently unprofitable.